Literature DB >> 23945445

Treatment response, symptom remission, and wellness in obsessive-compulsive disorder.

Samantha G Farris1, Carmen P McLean, Page E Van Meter, Helen Blair Simpson, Edna B Foa.   

Abstract

BACKGROUND: Obsessive-compulsive disorder (OCD) is defined both by intrusive, unwanted thoughts, images, or impulses and by repetitive behavioral or mental acts that are often performed to try to alleviate anxiety. The ultimate goal of treatment for OCD is to reduce the symptoms as well as help patients achieve "wellness." Currently, however, there are no widely accepted, empirically supported criteria for determining wellness in OCD.
METHOD: Building on previous research, the current study examined the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score that most reliably identified patients who responded to treatment, those who achieved symptom remission, and those who achieved wellness. The current study pooled data from 4 randomized controlled OCD treatment trials (N = 288), which took place between 1990 and 2011 at 2 academic sites. Participants (mean age = 36.8 years) had a primary diagnosis of DSM-IV-TR OCD (mean Y-BOCS score = 25.9).
RESULTS: Signal detection analyses showed that a pretreatment-to-posttreatment reduction of ≥ 35% on the Y-BOCS was most predictive of treatment response as defined by the Clinical Global Impressions (CGI)-Improvement scale. A posttreatment Y-BOCS score of ≤ 14 was the best predictor of symptom remission, whereas a score of ≤ 12 was the best predictor of wellness, as defined by symptom remission (defined by the CGI-Severity scale), good quality of life (as measured by the Quality of Life Enjoyment and Satisfaction Questionnaire), and a high level of adaptive functioning (as assessed by the Social Adjustment Scale-Self-Report). Because efficiency (0.86) and specificity (0.88) were highest at the cutoff of ≤ 12, this cutoff score was determined to be the best indicator of wellness.
CONCLUSIONS: The present findings support the convergent validity of the Y-BOCS with other measures of well-being (quality of life, adaptive functioning) and highlight the utility of a Y-BOCS score ≤ 12 as a solo indicator of wellness in outcome studies. The use of empirically supported criteria for defining wellness in OCD is recommended to facilitate comparisons across treatment outcome studies and to inform clinical treatment planning. TRIAL REGISTRATION: Pooled data analyzed in this study were from 4 clinical trials, 3 of which are registered at ClinicalTrials.gov (identifiers: NCT00045903, NCT00389493, NCT00316316). © Copyright 2013 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23945445      PMCID: PMC3959901          DOI: 10.4088/JCP.12m07789

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  33 in total

Review 1.  Kappa coefficients in medical research.

Authors:  Helena Chmura Kraemer; Vyjeyanthi S Periyakoil; Art Noda
Journal:  Stat Med       Date:  2002-07-30       Impact factor: 2.373

2.  Quality-of-life changes among patients with obsessive-compulsive disorder in a partial hospitalization program.

Authors:  A Bystritsky; S Saxena; K Maidment; T Vapnik; G Tarlow; R Rosen
Journal:  Psychiatr Serv       Date:  1999-03       Impact factor: 3.084

Review 3.  Quality of life in obsessive-compulsive disorder.

Authors:  L M Koran
Journal:  Psychiatr Clin North Am       Date:  2000-09

4.  Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure.

Authors:  J Endicott; J Nee; W Harrison; R Blumenthal
Journal:  Psychopharmacol Bull       Date:  1993

5.  The Yale-Brown Obsessive Compulsive Scale. II. Validity.

Authors:  W K Goodman; L H Price; S A Rasmussen; C Mazure; P Delgado; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1989-11

6.  Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale.

Authors:  S R Woody; G Steketee; D L Chambless
Journal:  Behav Res Ther       Date:  1995-06

7.  Social adjustment by self-report in a community sample and in psychiatric outpatients.

Authors:  M M Weissman; B A Prusoff; W D Thompson; P S Harding; J K Myers
Journal:  J Nerv Ment Dis       Date:  1978-05       Impact factor: 2.254

Review 8.  Assessment of severity and change in obsessive compulsive disorder.

Authors:  W K Goodman; L H Price
Journal:  Psychiatr Clin North Am       Date:  1992-12

9.  A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.

Authors:  Eric Hollander; Lorrin M Koran; Wayne K Goodman; John H Greist; Philip T Ninan; Haichen Yang; David Li; Luigi M Barbato
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

10.  The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.

Authors:  W K Goodman; L H Price; S A Rasmussen; C Mazure; R L Fleischmann; C L Hill; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1989-11
View more
  55 in total

1.  Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder.

Authors:  David Mataix-Cols; Lorena Fernández de la Cruz; Ashley E Nordsletten; Fabian Lenhard; Kayoko Isomura; Helen Blair Simpson
Journal:  World Psychiatry       Date:  2016-02       Impact factor: 49.548

2.  Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

Authors:  Helen Blair Simpson; Edna B Foa; Michael R Liebowitz; Jonathan D Huppert; Shawn Cahill; Michael J Maher; Carmen P McLean; James Bender; Sue M Marcus; Monnica T Williams; Jamie Weaver; Donna Vermes; Page E Van Meter; Carolyn I Rodriguez; Mark Powers; Anthony Pinto; Patricia Imms; Chang-Gyu Hahn; Raphael Campeas
Journal:  JAMA Psychiatry       Date:  2013-11       Impact factor: 21.596

3.  Defining treatment response and symptom remission for anxiety disorders in pediatric autism spectrum disorders using the Pediatric Anxiety Rating Scale.

Authors:  Carly J Johnco; Alessandro S De Nadai; Adam B Lewin; Jill Ehrenreich-May; Jeffrey J Wood; Eric A Storch
Journal:  J Autism Dev Disord       Date:  2015-10

4.  Patient adherence and treatment outcome with exposure and response prevention for OCD: Which components of adherence matter and who becomes well?

Authors:  Michael G Wheaton; Hanga Galfalvy; Shari A Steinman; Melanie M Wall; Edna B Foa; H Blair Simpson
Journal:  Behav Res Ther       Date:  2016-07-29

5.  Behavioral avoidance predicts treatment outcome with exposure and response prevention for obsessive-compulsive disorder.

Authors:  Michael G Wheaton; Marina Gershkovich; Thea Gallagher; Edna B Foa; H Blair Simpson
Journal:  Depress Anxiety       Date:  2018-02-02       Impact factor: 6.505

Review 6.  Obsessive-compulsive disorder.

Authors:  Dan J Stein; Daniel L C Costa; Christine Lochner; Euripedes C Miguel; Y C Janardhan Reddy; Roseli G Shavitt; Odile A van den Heuvel; H Blair Simpson
Journal:  Nat Rev Dis Primers       Date:  2019-08-01       Impact factor: 52.329

7.  REDUCED DISGUST PROPENSITY IS ASSOCIATED WITH IMPROVEMENT IN CONTAMINATION/WASHING SYMPTOMS IN OBSESSIVE-COMPULSIVE DISORDER.

Authors:  Alison J Athey; Jason A Elias; Jesse M Crosby; Michael A Jenike; Harrison G Pope; James I Hudson; Brian P Brennan
Journal:  J Obsessive Compuls Relat Disord       Date:  2015-01-01       Impact factor: 1.677

8.  Task-based fMRI predicts response and remission to exposure therapy in obsessive-compulsive disorder.

Authors:  David Pagliaccio; Rachel Middleton; Dianne Hezel; Shari Steinman; Ivar Snorrason; Marina Gershkovich; Raphael Campeas; Anthony Pinto; Page Van Meter; H Blair Simpson; Rachel Marsh
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-23       Impact factor: 11.205

9.  Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies.

Authors:  Carmen P McLean; Laurie J Zandberg; Page E Van Meter; Joseph K Carpenter; Helen Blair Simpson; Edna B Foa
Journal:  J Clin Psychiatry       Date:  2015-12       Impact factor: 4.384

10.  Refining Clinical Judgment of Treatment Response and Symptom Remission Identification in Childhood Anxiety Using a Signal Detection Analysis on the Pediatric Anxiety Rating Scale.

Authors:  Carly J Johnco; Alison Salloum; Adam B Lewin; Eric A Storch
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-11       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.